Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an announcement.
Shanghai Junshi Biosciences Co., Ltd. has announced an extraordinary general meeting (EGM) scheduled for September 26, 2025, to discuss several key proposals. These include the election of an Independent Non-executive Director, amendments to internal management policies, changes in registered capital, and the abolishment of the Board of Supervisors. Additionally, the meeting will address the 2025 A and H Share Option Incentive Schemes, which aim to grant share options to directors and substantial shareholders, enhancing stakeholder engagement and potentially impacting the company’s strategic direction.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$18.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biotechnology industry. The company focuses on the development and commercialization of innovative therapies, primarily in the field of immuno-oncology.
Average Trading Volume: 13,577,005
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.42B
See more data about 1877 stock on TipRanks’ Stock Analysis page.